The Zhitong Finance App learned that Moderna (MRNA.US), a global biotechnology leader known for its COVID-19 vaccines based on m-RNA technology, announced on Wednesday local time that the company has cooperated with ChatGPT developer OpenAI to deploy ChatGPT Enterprise across its entire business line to comprehensively accelerate the company's drug development process.

According to media reports, according to this major collaboration, by the end of this week, around 3,000 employees at the Massachusetts biotech company Moderna will be able to use ChatGPT Enterprise based on OpenAI's most advanced big language model GPT-4. However, the financial terms of this cooperation agreement have yet to be disclosed.

According to information, the two companies began collaborating in early 2023 and launched an exclusive customized version of ChatGPT called mChat. Since its launch, more than 80% of Moderna's employees have used this version for daily drug development work.

The two companies jointly stated in a statement: “This initial collaboration has accelerated the development of artificial intelligence culture and comprehensively promoted the deployment of ChatGPT Enterprise and enhanced important features such as advanced microlevel analysis, image generation, and GPTS.”

Moderna CEO Stacimane Bancel said: “Moderna has ambitious plans to launch multiple blockbuster products over the next few years, and partnering with tech companies like OpenAI is critical to our ability to scale up and maximize our impact on patients.”

OpenAI CEO Sam Ultrman said, “People are really talking about how artificial intelligence will one day cure diseases, and I think this is a very meaningful first step.”

Previously, Recursion Pharmaceuticals (RXRX.US) had fully cooperated with AI chip leader Nvidia (NVDA.US) in 2023 to jointly develop a drug development process based on artificial intelligence technology.

“Golden Track” certified by the “Godfather of AI”! “AI+ Healthcare” is the segment that Nvidia is most concerned about

As the head of Nvidia, Hwang In-hoon, the “Godfather of AI,” has more than once called “AI+ medical technology/biology” “the next amazing revolution” in the field of technology in various public forums. He even said at a recent conference that the era where everyone had to learn computers is over; biology and medicine are the future of humanity. Over the past two years, Nvidia's venture capital division has invested a significant portion of its capital in drug development — in 2023 alone, Nvidia invested in eight biotech startups focused on drug development.

The application of AI technology in the medical field has made many significant advances, particularly in novel drug discovery, simulated gene editing, disease diagnosis, patient monitoring, and medical image analysis. For example, Nvidia has provided powerful computing hardware support and AI software tool support for the medical field through its BioNemo cloud service and other AI platforms with high computing power support, speeding up the process of drug development and disease diagnosis and treatment. And behind technologies such as drug discovery and medical imaging incorporating AI models, it is probably inseparable from Nvidia GPUs and the Nvidia software ecosystem to provide strong computing power support.

Needless to say, as AI technology continues to advance, there will inevitably be more innovative medical applications in the future, such as virtual patients simulated by AI for drug testing and accurate gene editing simulation processes using AI.

According to GMI Research's latest research report, the healthcare market value incorporating AI technology is only about US$10.4 billion in 2022, and is expected to reach US$189.9 billion by 2030, with a compound annual growth rate (CAGR) of 43.7% during this period. GMI Research predicts that AI is expected to be fully applied to fields such as medical imaging, drug discovery, medical surgery assistance robots, and gene-level precision medicine, drastically reducing the product innovation cycle, comprehensively improving the accuracy rate of modern medicine, and covering a wider range of patients in the same period of time.